Michael Savetsky, MD
Cornea and External Diseases Specialist · Culver City, CANPI 1255598819
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Eyepoint US, Inc. accounts for 66.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $30,641 and has fallen 91.7% since, to $2,530 in 2025. Among cornea and external diseases specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $321.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$42K
- Oyster Point Pharma, Inc.$10K
- Mallinckrodt Enterprises LLC$4K
- Mallinckrodt Hospital Products Inc.$3K
- Tarsus Pharmaceuticals, Inc.$3K
- Sun Pharmaceutical Industries Inc.$665
- plus $2K from 11 others
Across 3 payments — averaging $4487.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$10K
- Eyepoint US, Inc.$3K
What the payments were for
- Consulting fees$25,30040%
- Speaking & faculty fees$29,90047%
- Travel & lodging$2,7584%
- Food & beverage$4,8568%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 54 | $41,853 |
| Oyster Point Pharma, Inc. | 18 | $9,987 |
| Mallinckrodt Enterprises LLC | 15 | $3,944 |
| Mallinckrodt Hospital Products Inc. | 9 | $2,530 |
| Tarsus Pharmaceuticals, Inc. | 20 | $2,523 |
| Sun Pharmaceutical Industries Inc. | 27 | $665 |
| Alcon | 9 | $452 |
| Amgen(2 entities) | 23 | $429 |
| Dompe US, Inc. | 8 | $198 |
| AbbVie | 3 | $172 |
| Sight Sciences, Inc. | 2 | $97 |
| Novartis | 2 | $40 |
| Glaukos Corporation | 1 | $30 |
| Eyevance Pharmaceuticals LLC | 2 | $29 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXYCU$41,426
- TYRVAYA$9,714
- ACTHAR$6,072
- TEPEZZA$129
- XEN GLAUCOMA TREATMENT SYSTEM$118
- Hydrus Microstent$114
How this compares
$63,007 in reported general payments places this provider in the 90th percentile of 50 cornea and external diseases specialist providers in California.
See all cornea and external diseases specialist providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 191 | $188,726 |
| Cyclosporine | 182 | $91,493 |
| XdemvyLotilaner | 38 | $68,827 |
| XiidraLifitegrast | 33 | $48,665 |
| LumiganBimatoprost | 59 | $25,331 |
| CequaCyclosporine | 15 | $12,885 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 28 | $8,981 |
| Alphagan PBrimonidine Tartrate | 33 | $8,085 |
| Prednisolone Acetate | 236 | $6,948 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $5,198 |
| MoxifloxacinMoxifloxacin Hcl | 172 | $4,429 |
| Latanoprost | 379 | $3,797 |
| Travoprost | 11 | $2,611 |
| Ketorolac Tromethamine | 157 | $2,249 |
| Bromfenac Sodium | 18 | $1,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $172 | $222,142283 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,523 | $68,82738 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $665 | $12,88515 claims |
| AlconSimbrinza | $452 | $8,98128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 cornea and external diseases specialist providers in California.
Other cornea and external diseases specialist in Culver City
- Sumit GargIrvine$808K
- Jillian ChongBeverly Hills$113K
- Tyson KimSan Francisco$91K
- Edward MancheStanford$78K
- Michael SaidelSonoma$51K
- Matthew WadeIrvine$38K
- Lawrence ChaoIrvine$36K
- William ChristianSanta Monica$33K
- Alexander FosterEncinitas$29K
- Jimmy LeeIrvine$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.